-
Sector Analysis
Insomnia Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Insomnia Market Report Overview The Insomnia market across the 7MM (7MM: the US, France, Germany, Italy, Spain, the UK, and Japan) was valued at $3.2 billion in 2022. Steady growth is anticipated at a CAGR of more than 2% from 2022 to 2032, due to the launch of four novel pipeline agents - Hetlioz, SM-1, vornorexant, and sunobinop. The insomnia market research report offers an overview of insomnia, including its epidemiology, symptoms, diagnosis, and disease management. The report offers key...
-
Sector Analysis
Generalized Pustular Psoriasis (GPP) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Generalized Pustular Psoriasis Marketed and Pipeline Drugs Report Overview By 2028, GlobalData estimates that the highest prevalence of GPP cases will be in South Korea and China. Generalized Pustular Psoriasis (GPP) is a subtype of psoriasis in which patients exhibit painful episodes of sterile pustules in their skin. Companies such as AbbVie and academic institutions both are investing heavily in the the clinical trials for GPP. Key Mechanism of Action (Marketed) ·       Receptor Agonist ·       Biological Factor Inhibitor ·       Receptor...
-
Sector Analysis
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Glioblastoma Multiforme (GBM) Marketed and Pipeline Drugs Report Overview In 2023, the highest incident cases of Glioblastoma Multiforme (GBM) were from China and India. Glioblastoma Multiforme is a fast-growing and aggressive brain tumor. It is also referred to as a grade IV astrocytoma. GBM invades the nearby brain tissue but generally does not spread to distant organs. There are only a handful of innovator treatment options approved for the treatment of GBM and most conventional marketed drugs are small molecules,...
-
Sector Analysis
Anal Cancer (AC) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Anal Cancer Marketed and Pipeline Drugs Report Overview Anal cancer develops in the cells and tissue of the skin lining on either the inside or outside of the anus. The development of anal cancer is directly linked to a complex inflammatory process secondary to infections such as (HPV) types 16 and 18. The progression of this inflammatory process heralds the development of anal intraepithelial neoplasia (AIN), or squamous cell carcinoma (SCC) in situ (Bowen disease), which is a pre-malignant condition....
-
Sector Analysis
Rheumatoid Arthritis (RA) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Reasons to buy the ‘Rheumatoid Arthritis (RA)’ marketed and pipeline drugs assessment report: Get a comprehensive overview of the rheumatoid arthritis market including disease epidemiology, treatment guidelines, clinical trials, deals, and an assessment of marketed and pipeline drugs. Get an insight into MoA, RoA, and molecule types for the leading marketed and pipeline drugs in RA. Assess the pricing and reimbursement of rheumatoid arthritis marketed and pipeline drugs. Get a detailed assessment of the clinical trials taking place within the...
-
Sector Analysis
Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Bacterial Vaginosis (BV) Marketed and Pipeline Drugs Report Overview Bacterial Vaginosis is the most commonly occurring vaginal infection in women of reproductive age. It occurs when the healthy vaginal flora is dominated by BV-associated bacteria (BVAB). The most common BVAB includes Gardnerella vaginalis, Atopobium vaginae, Megasphaera spp., Prevotella spp., and Sneathia spp. BVAB is caused by almost 35 unique bacterial species: a few of them are less frequently detected, including species such as Peptostreptococcus spp., Aerococcus, Anaerococcus, Gemella, and Veillonella...
-
Sector Analysis
Menopausal Disorders (MD) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Menopausal Disorders (MD) Marketed and Pipeline Drugs Report Overview Menopausal disorders are a permanent cessation of menstruation resulting in the loss of ovarian follicle development. In 2023, the highest number of prevalent cases of menopausal disorders were registered in India and China. Treatment guidelines for MD are well-established globally and at the country level and are updated periodically. For instance, in 2023, the US and China updated guidelines. In the US, guidelines were provided by the North American Menopause Society...
-
Sector Analysis
Myasthenia Gravis Market Opportunity Assessment, Epidemiology, Clinical Trials, Unmet Needs and Forecast to 2032
Myasthenia Gravis Market Report Overview The Myasthenia Gravis (MG) market size for the seven major markets (7MM) was $3 billion in 2022. The market will register a CAGR of more than 8% during 2022-2032. MG is the most common neuromuscular disorder, although it is still classified as a rare disease. It is an autoimmune and neuromuscular disease that is characterized by muscle weakness and fatigue. In most patients, the disease is initially localized and limited to the eye muscles. This...
-
Sector Analysis
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Assessment, Clinical Trials and Competitive Landscape
Lennox-Gastaut Syndrome (LGS) Marketed and Pipeline Drugs Report Overview Lennox-Gastaut Syndrome (LGS) is a severe form of epilepsy that typically becomes apparent during infancy or early childhood. Affected children experience several different types of seizures, such as atonic, tonic, and atypical absence seizures. Children with LGS may also develop cognitive dysfunction, delays in reaching developmental milestones, and behavioral problems. Key Mechanism of Action (Marketed) ·       Receptor Agonists ·       Ion Channel Blockers ·       Enzyme Inhibitors ·       Receptor Antagonists ·       Transporter Inhibitors...